New York – October 05, 2026 -- A new multisector coalition launched the 30x30x50 Brain Challenge, pledging to cut stroke incidence by 30 percent and increase primary-care cognitive screening by 50 percent across 30 global cities by 2031.
Atria-coordinated coalition unites pharma, tech and the UN behind brain health delivery
The International Brain Health Coalition (IBC), coordinated by the Atria Research and Global Health Institute (ARGHI), brings together patients, multilateral institutions including the United Nations, and organizations spanning medicine, technology, and finance. Collaborators include Eli Lilly and Company, Bristol Myers Squibb, Microsoft, the Royal Bank of Canada, the American Heart Association, UN Women, Western University, and the AI-Mind Institute in Norway.
Dr. David Dodick, Chair of the IBC and Chief Science and Medical Officer at the Atria Health Institute, said the coalition was built to close an "execution failure" in deploying existing prevention science rather than generating new evidence.
London, Ontario and Oslo named as launch cities for implementation trials
London, Ontario, Canada hosts the CanDo Brain Health Implementation Initiative, a two-year trial enrolling up to 800 participants in an AI-and-human coaching model targeting blood pressure, activity, and sleep, anchored by the Western Institute for Neuroscience at Western University.
Oslo, Norway anchors the Coalition's European effort through the AI-Mind research environment at Oslo University Hospital and the University of Oslo, led by Dr. Ira Haraldsen, in partnership with BrainSymph. The Oslo program combines multimodal AI, EEG, blood-based biomarkers, and longitudinal home monitoring to identify cognitive decline risk before dementia onset, with ties to European research, regulatory, and commercialization programs.
Industry partners flag biomarker and behavioral-data roles in prevention model
Jennifer Oleksiw of Eli Lilly and Company noted that Alzheimer's-related brain changes can begin up to 20 years before symptoms appear, and said the Coalition will assess how blood-based biomarkers could support earlier detection in primary care. Bristol Myers Squibb's Wendy Short Bartie said the initiative's value lies in converting existing knowledge into scalable delivery models across health systems and communities.
Arianna Huffington of Thrive Global said the platform's behavior-change technology can deliver personalized health nudges to populations at scale, calling this reach essential to making the Coalition's goals feasible.
UN Women and Women's Alzheimer's Movement push gender-specific framing
UN Women's Sima Bahous said women represent nearly two-thirds of Alzheimer's patients and the majority of caregivers, and that the Coalition has embedded a women's health lens into its structure from inception. Maria Shriver, founder of the Women's Alzheimer's Movement at Cleveland Clinic, said the effort moves Alzheimer's prevention from the margins into mainstream everyday care.
Dr. Mitchell Elkind of the American Heart Association said the Coalition's goals align with the organization's existing brain health and stroke priorities.